HAMBURG, GERMANY / ACCESSWIRE / February 4, 2022 / Evotec SE (Frankfurt Stock Exchange, MDAX/TecDAX, ISIN: DE 000 566480 9, WKN 566480; NASDAQ) announces today that the Company has been informed by Bayer about a decision to discontinue the development of the investigational P2X3 receptor antagonist eliapixant (BAY1817080), which stems from a former Evotec/Bayer multi-target research alliance.
Following a review of the available data, Bayer concluded that the overall benefit no longer outweighs the risk in the actively pursued indications.
As a consequence of Bayer’s decision, Evotec regains the rights to all P2X3 assets. The Company will evaluate the underlying data as soon as they are made available and will evaluate all options.
This decision has no impact on the overall strategic goals as outlined in Action Plan 2025.
Contact:
Dr Werner Lanthaler
Chief Executive Officer
Evotec SE
Manfred Eigen Campus
Essener Bogen 7, 22419 Hamburg, Germany
Phone: +49.(0)40.560 81-242
werner.lanthaler@evotec.com
SOURCE: Evotec AG
View source version on accesswire.com:
https://www.accesswire.com/687278/Bayer-Discontinues-Clinical-Development-Candidate-Eliapixant-BAY1817080-Evotec-Regains-the-Rights-to-all-P2X3-Assets
Findings reflect the rigorous clinical standards behind DS-01®'s position as the #1 digestive health probiotic…
Insurers are investing in data, governance and skills, but only one in three has the…
The Best Facelift Surgeon in the U.S. is Dr. Santos SEATTLE, WASHINGTON / ACCESS Newswire…
The Best Plastic Surgeon in Seattle Is Dr. Javad Sajan SEATTLE, WA / ACCESS Newswire…
Validation is expected to accelerate TempraMed's path to payor reimbursement for product portfolioHighlightsROI model validated…
RED BANK, N.J., Jan. 13, 2026 /PRNewswire/ -- Conscientia Health is proud to announce that it…